Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer
Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54%
Strong efficacy signal observed in non-squamous NSCLC patients previously treated with the PD-1 inhibitor pembrolizumab, with median OS of 26.7 months and 91% ORR, including two complete responses
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of results from the CANFOUR trial with nadunolimab in combination with chemotherapy in the peer reviewed journal Lung Cancer. 40 patients with advanced NSCLC were treated with nadunolimab in combination with cisplatin/gemcitabine or carboplatin/pemetrexed for 4-6 cycles before continuing with nadunolimab as monotherapy or together with only gemcitabine or pemetrexed. The trial showed a manageable safety profile and encouraging median survival times, especially in patients with prior treatment with checkpoint inhibitors.
"These positive data published in Lung Cancer describe an important potential opportunity for nadunolimab, with possibilities to address a major unmet medical need" said Damian Marron, interim CEO of Cantargia. "We are particularly encouraged by the strong signal in the non-squamous NSCLC patients post PD-1 inhibitor treatment".
Lung cancer is one of the most common malignances worldwide and a leading cause of cancer-related deaths, with 84% of cases of the non-small cell lung cancer (NSCLC) type [1]. Immune checkpoint inhibitors targeting programmed death (ligand) 1 (PD-1/PD-L1) form part of the standard of care alongside chemotherapy for patients with advanced/metastatic NSCLC [2]. Treatment of NSCLC with immune checkpoint inhibitors can markedly improve tumor response rates and prolong survival, but not all patients respond to treatment and the development of treatment resistance is frequent [3, 4].
The CANFOUR Phase 2a trial with 40 advanced/metastatic NSCLC patients investigated nadunolimab in combination with cisplatin/gemcitabine (NCG) or carboplatin/pemetrexed (NCP) in first-line (1L), or in second-line (2L) after relapsing on pembrolizumab. Nadunolimab at doses of 1, 2.5 or 5 mg/kg were combined with chemotherapy for 4-6 cycles, followed by nadunolimab monotherapy or together with only gemcitabine or pemetrexed. Promising efficacy was reported with an OS of 13.7 months, which is observed to be better than historical references from randomized clinical trials of cisplatin/gemcitabine or platinum/pemetrexed in advanced NSCLC (median OS 10.3 and 11.3 months) [5,6].
Interestingly, highest efficacy was seen in patients previously treated with pembrolizumab (n=17) as compared to treatment naïve patients (n=23) (ORR 71% vs 44%; OS 15.7 vs 11.5 months). The 2L post-pembrolizumab patients had a markedly different tumor microenvironment at baseline with higher number of IL1RAP-positive immune cells, CD163+ macrophages, CD56+ NK cells and CD8+ T cells. Best response was seen in 2L non-squamous patients (n=11) which showed an outstanding ORR of 91%, PFS of 10.4 months and OS of 26.7 months, including two complete responders.
20 patients continued with nadunolimab monotherapy after having discontinued chemotherapy. One patient attained a complete response during monotherapy treatment, indicating a continued clinical effect of nadunolimab after completion of chemotherapy.
The combination showed a manageable safety profile with neutropenia being the most frequent reported adverse event.
The results support further investigation of the potential benefit in patients with non-squamous histology who previously progressed on immune checkpoint inhibitors, and to assess the potential benefit of continued nadunolimab monotherapy.
The publication, titled "Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet", by Paulus et al, is available online at the Lung Cancer | Journal | ScienceDirect.com by Elsevier and will be published Cantargia's web page.
References[1] Kratze et al. Cancer 2024 130(8) 1330-1348[2] Owen et al JCO Oncol Pract 2024 20(7) 893-898[3] Bagshi et al Ann Rev Path 2021 16 223-249[4] Jenkins et al Br J Cancer 2018 118(1) 9-16[5] Scagliotti et al J Clin Onc 2008 26(21) 3543-3551[6] Gandhi et al N Engl J Med 2018 378(22) 2078-2092
For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: damian.marron@cantargia.com
About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
About nadunolimab (CAN04)The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316, evaluates nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 40 NSCLC patients with median PFS of 7.2 months and a response rate of 55%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase 1b/2 trial TRIFOUR, NCT05181462, also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine.
AttachmentsCantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer
SOURCE: Cantargia
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Bayern Munich's Adam Aznou scheduled for Everton medical this weekend
Everton should be able to wrap up a purchase of Bayern Munich fullback Adam Aznou soon. Sport Bild reports that the 19-year-old has indeed lodged a transfer request with his Bundesliga club. Earlier this week, Kicker confirmed that Bayern's previous negotiations with Getafe CF had produced nothing but a busted deal, Fabrizio Romano now reports that the German and English club have reached full agreement on the transfer. Romano confirms numbers originating in a report from The Athletic earlier today. Bayern shall receive a base-transfer-fee for their young talent. An additional €3m in bonuses have beeb tacked on. Aznou, per Romano, will undergo his Everton medical this weekend. Aznou was recalled by Bayern Munich early from his recent loan stint with Real Valladolid in order to participate in the recent club World Cup. The teenager nevertheless wasn't able to take advantage of the opportunity accorded to him. Aznou logged only eight minutes as a substitute in Bayern's opening group stage fixture. GGFN |
Yahoo
36 minutes ago
- Yahoo
Melinda French Gates says she refuses to give her 22-year-old daughter any money for her shopping business — here's why
With an estimated net worth of $30.7 billion, Melinda French Gates can easily bankroll her daughter's business without breaking a sweat. But at a recent summit, the billionaire philanthropist confirmed she is not funding the new venture. Gates didn't say which of her two daughters she was referring to, but 22-year-old Phoebe Gates recently launched Phia, an AI-powered shopping app, according to The Verge. Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast) You don't have to be a millionaire to gain access to this $1B private real estate fund. In fact, you can get started with as little as $10 — here's how 'I wouldn't put money into it,' Gates told host Amanda Davies at the *Power of Women's Sports Summit presented by e.l.f. Beauty in London. By holding back her financial support, Gates says her daughter gets the chance to test and validate the business idea with real investors and customers. If it's a 'real business,' Gates says, the venture will eventually find people willing to back it. Phia has already attracted outside capital. According to GeekWire, the startup has raised $850,000, including $100,000 from Soma Capital, a $250,000 Stanford social entrepreneurship grant and $500,000 from angel investors such as Kris Jenner and Desiree Gruber. Phoebe Gates and her co-founder, Sophia Kianni, have also secured a podcast deal to promote the venture. Her journey offers some valuable lessons for anyone looking to start a business. Look for real-world traction Despite the flashy headlines, most startups fail. Roughly 90% eventually collapse, according to the Founders Forum Group, with 42% failing because they couldn't meet market demand. In other words, the odds are stacked against you, and the most common pitfall is building something nobody wants to pay for. To avoid this trap, try to find relatively cheap and quick ways to validate your business idea. Pitch the idea to angel investors or industry experts to see if they would bet real money on the venture's success. Better yet, look for paying customers to validate your business idea before you sink too much of your own money into it. Read more: Want an extra $1,300,000 when you retire? Dave Ramsey says — and that 'anyone' can do it Customers are the best source of funding According to the Small Business Administration, about 14% of small business owners relied on friends and family for funding in 2023. More often, though, entrepreneurs turned to self-funding methods like credit cards or formal channels like banks or government agencies. One of the most popular sources of funding was the business itself. Nearly 31% of small business owners relied on the corporation's earned and retained earnings to fund and grow their ventures. In other words, paying customers can be your best source of startup capital. If you're launching something new, think about how to attract real customers first. For example, you could build a waitlist of clients who have already signalled interest in your product or service. You might also collect early deposits or presale revenue to help fund development. Getting those early customers will take time and effort, especially in marketing, but it brings two major benefits: proving there's real demand and creating early cash flow to support your growth. What to read next Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now Accredited investors can now buy into this $22 trillion asset class once reserved for elites – and become the landlord of Walmart, Whole Foods or Kroger without lifting a finger. Here's how Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Should You Invest in Spotify (SPOT)?
Sands Capital, an investment management company, released its 'Sands Capital Technology Innovators Fund' Q2 2025 investor letter. A copy of the letter can be downloaded here. Technology Innovators focus on pioneering businesses worldwide that serve as key drivers or beneficiaries of significant long-term changes driven by technology. The fund returned 26.0% (net) in the second quarter compared to a 21.9% return for the benchmark, MSCI ACWI Info Tech and Communication Services Index. Easing geopolitical concerns, renewed AI optimism, resilient macroeconomic data, strong corporate earnings, and technical tailwinds boosted the markets for a quick recovery in the quarter. You can check the fund's top 5 holdings to know more about its best picks for 2025. In its second-quarter 2025 investor letter, Sands Capital Technology Innovators Fund highlighted stocks such as Spotify Technology S.A. (NYSE:SPOT). Headquartered in Luxembourg City, Luxembourg, Spotify Technology S.A. (NYSE:SPOT) offers audio streaming subscription services. Spotify Technology S.A. (NYSE:SPOT) shares posted a return of -11.80% over the past month and appreciated by 111.70% over the last 12 months. On July 24, 2025, Spotify Technology S.A. (NYSE:SPOT) stock closed at $681.42 per share, with a market capitalization of $139.729 billion. Sands Capital Technology Innovators Fund stated the following regarding Spotify Technology S.A. (NYSE:SPOT) in its second quarter 2025 investor letter: "Spotify Technology S.A. (NYSE:SPOT) is the world's largest subscription streaming audio service by market share. Recorded music has seen significant distribution shifts—from vinyl to cassette to CDs—over the past 50 years. Today, streaming accounts for the bulk of industry revenue, and we view streaming as the natural end-state, given the consumer value proposition and balance of power between artists and labels. Within streaming, Spotify has outsized market share and user engagement. This has resulted in relatively inelastic demand and, in turn, pricing power. We ultimately view the addressable market as anyone with internet access globally. Unlike with video streaming, consumers tend to subscribe to only a single audio streaming service. Spotify's leadership position has become further entrenched with music labels' growing dependence on streaming revenue. Over our five-year horizon, we expect gross margin improvement from advertising and partnership agreements with labels, with operating margin improvement also driven by cost discipline." A person wearing headphones listening to an audio streaming service. Spotify Technology S.A. (NYSE:SPOT) is in 25th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 106 hedge fund portfolios held Spotify Technology S.A. (NYSE:SPOT) at the end of the first quarter, which was 101 in the previous quarter. While we acknowledge the potential of Spotify Technology S.A. (NYSE:SPOT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Spotify Technology S.A. (NYSE:SPOT) and shared the list of best global stocks to buy. In its Q2 2025 investor letter, Rowan Street Capital reaffirmed its long-term conviction in Spotify Technology S.A. (NYSE:SPOT). In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
